Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GHASSAN E HADI

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1558497891
CMS profile
70065
Location
UPLAND, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$50.93

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $50.93 3

By paying entity

PY2023 · entire year · sorted by reported total

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GHASSAN E HADI

NPI 1558497891 · CMS profile ID 70065

Allopathic & Osteopathic Physicians / Internal Medicine

UPLAND, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1558497891?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GHASSAN E HADI, NPI 1558497891, CMS profile ID 70065. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1558497891?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). GHASSAN E HADI, NPI 1558497891, CMS profile ID 70065. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1558497891?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
GHASSAN E HADI, NPI 1558497891, CMS profile ID 70065, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1558497891?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $50.93 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $12.2009/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 984085383 CMS
Medtronic, Inc. $24.3304/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025949475 CMS
Novartis Pharmaceuticals Corporation $14.4002/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992244849 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $263.01 5
PY2020 $24.75 1
PY2021 $62.66 3
PY2022 $58.25 3
PY2023 $50.93 3
PY2024 $113.96 5
PY2025 $389.94 16

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $54,708.88 2
PY2024 Principal investigator $420,960.28 70
PY2023 Principal investigator $204,323.13 66
PY2022 Recipient $16,223.02 2
PY2022 Principal investigator $153,397.33 18
PY2021 Principal investigator $215,215.05 24
PY2020 Principal investigator $212,670.33 84
PY2019 Principal investigator $457,066.36 176

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

84 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan, Inc. $10,755.83 12/31/2020 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721315447
Principal investigator 1 Allergan, Inc. $700.00 12/22/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
OPEN-LABEL EXTENSION STUDY OF RELAMORELIN FOR THE TREATMENT OF DIABETIC GASTROPARESIS (DG) No dispute reported 06/30/2026 721313607
Principal investigator 1 Allergan, Inc. $385.00 12/15/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 721311817
Principal investigator 1 Allergan, Inc. $2,118.50 11/20/2020 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 721309365
Principal investigator 1 Allergan, Inc. $169.00 11/17/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 721308407
Principal investigator 1 Allergan, Inc. $1,805.00 11/16/2020 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721308311
Principal investigator 1 Allergan, Inc. $86.00 11/05/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 721306769
Principal investigator 1 Allergan, Inc. $115.00 10/22/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 721304957
Principal investigator 1 Allergan, Inc. $7,185.80 10/19/2020 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721303789
Principal investigator 1 Allergan, Inc. $1,947.50 10/16/2020 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) No dispute reported 06/30/2026 721303353
Principal investigator 1 Allergan, Inc. $115.00 10/15/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 721302723
Principal investigator 1 Allergan, Inc. $86.00 10/15/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 46-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 LONGTERM STUDY WITH A 6-WEEK RANDOMIZED-WITHDRAWAL PERIOD TO EVALUATE THE SAFETY AND No dispute reported 06/30/2026 721302755
Principal investigator 1 Allergan, Inc. $3,750.00 10/01/2020 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721301309
Principal investigator 1 Allergan, Inc. $327.00 09/29/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 46-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 LONGTERM STUDY WITH A 6-WEEK RANDOMIZED-WITHDRAWAL PERIOD TO EVALUATE THE SAFETY AND No dispute reported 06/30/2026 721300837
Principal investigator 1 Allergan, Inc. $115.00 09/24/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 721300427
Principal investigator 1 AKEBIA THERAPEUTICS INC $4,340.00 09/22/2020 Non-covered Recipient Entity
GHASSAN HADI MD INC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753286425
Principal investigator 1 Allergan, Inc. $315.00 09/22/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
OPEN-LABEL EXTENSION STUDY OF RELAMORELIN FOR THE TREATMENT OF DIABETIC GASTROPARESIS (DG) No dispute reported 06/30/2026 721299091
Principal investigator 1 Allergan, Inc. $315.00 09/22/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 46-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 LONGTERM STUDY WITH A 6-WEEK RANDOMIZED-WITHDRAWAL PERIOD TO EVALUATE THE SAFETY AND No dispute reported 06/30/2026 721299179
Principal investigator 1 Allergan, Inc. $315.00 09/22/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 721299865
Principal investigator 1 PFIZER INC. $10,000.00 09/22/2020 Non-covered Recipient Entity
Upland Clinical Research
A PHASE 2 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBOCONTROLLED DOSERANGING DOSEFINDING PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF06865571 DGAT2I ALONE AND WHEN COADMINISTERED WITH PF05221304 ACCI IN ADULT PARTICIPANTS WITH BIOPSYCONFIRMED NONALCOHOLIC STEATOHEPATITIS AND FIBROSIS STAGE 2 OR 3 No dispute reported 06/30/2026 742921745
Principal investigator 1 Allergan, Inc. $4,124.90 09/18/2020 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721298693
Principal investigator 1 Allergan, Inc. $2,250.00 09/17/2020 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) No dispute reported 06/30/2026 721298413
Principal investigator 1 Allergan, Inc. $200.00 09/17/2020 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) No dispute reported 06/30/2026 721298473
Principal investigator 1 Allergan, Inc. $327.00 09/08/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 46-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 LONGTERM STUDY WITH A 6-WEEK RANDOMIZED-WITHDRAWAL PERIOD TO EVALUATE THE SAFETY AND No dispute reported 06/30/2026 721296057
Principal investigator 1 Allergan, Inc. $435.00 08/27/2020 Non-covered Recipient Entity
WESTERN INSTITUTIONAL REVIEW BOARD
OPEN-LABEL ROLLOVER STUDY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) No dispute reported 06/30/2026 721293637
Principal investigator 1 Allergan, Inc. $955.00 08/27/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 721293861
Principal investigator 1 Allergan, Inc. $385.00 08/21/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 721292075
Principal investigator 1 Allergan, Inc. $315.00 08/21/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 46-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 LONGTERM STUDY WITH A 6-WEEK RANDOMIZED-WITHDRAWAL PERIOD TO EVALUATE THE SAFETY AND No dispute reported 06/30/2026 721292561
Principal investigator 1 Allergan, Inc. $420.00 08/21/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 721292981
Principal investigator 1 Allergan, Inc. $327.00 08/21/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 46-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 LONGTERM STUDY WITH A 6-WEEK RANDOMIZED-WITHDRAWAL PERIOD TO EVALUATE THE SAFETY AND No dispute reported 06/30/2026 721293005
Principal investigator 1 Allergan, Inc. $2,118.50 08/20/2020 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 721291633
Principal investigator 1 Allergan, Inc. $4,694.90 08/19/2020 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721291393
Principal investigator 1 Allergan, Inc. $2,014.00 08/19/2020 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) No dispute reported 06/30/2026 721291517
Principal investigator 1 Allergan, Inc. $1,121.00 08/13/2020 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
Open-label Extension Study of Relamorelin for the treatment of diabetic gastroparesis (DG) No dispute reported 06/30/2026 721290231
Principal investigator 1 AKEBIA THERAPEUTICS INC $778.50 08/04/2020 Non-covered Recipient Entity
GHASSAN HADI MD INC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753286053
Principal investigator 1 Allergan, Inc. $1,691.00 07/22/2020 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) No dispute reported 06/30/2026 721286365
Principal investigator 1 Allergan, Inc. $950.00 07/22/2020 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) No dispute reported 06/30/2026 721286479
Principal investigator 1 Allergan, Inc. $1,762.25 07/20/2020 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721285539
Principal investigator 1 AKEBIA THERAPEUTICS INC $20,536.55 07/13/2020 Non-covered Recipient Entity
GHASSAN HADI MD INC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753285553
Principal investigator 1 Allergan, Inc. $54.15 06/29/2020 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721282161
Principal investigator 1 Allergan, Inc. $1,301.50 06/26/2020 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
Open-label Extension Study of Relamorelin for the treatment of diabetic gastroparesis (DG) No dispute reported 06/30/2026 721282129
Principal investigator 1 AKEBIA THERAPEUTICS INC $223.20 06/24/2020 Non-covered Recipient Entity
GHASSAN HADI MD INC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753284955
Principal investigator 1 Allergan, Inc. $435.00 06/16/2020 Non-covered Recipient Entity
WESTERN INSTITUTIONAL REVIEW BOARD
OPEN-LABEL ROLLOVER STUDY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) No dispute reported 06/30/2026 721279747
Principal investigator 1 Allergan, Inc. $2,118.50 06/02/2020 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 721278485
Principal investigator 1 Allergan, Inc. $385.00 05/26/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 721277173
Principal investigator 1 Allergan, Inc. $54.15 05/25/2020 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721277033
Principal investigator 1 Allergan, Inc. $950.00 05/25/2020 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) No dispute reported 06/30/2026 721277037
Principal investigator 1 Allergan, Inc. $3,477.00 05/20/2020 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721275801
Principal investigator 1 Allergan, Inc. $3,695.50 05/20/2020 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) No dispute reported 06/30/2026 721275949
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,890.00 05/14/2020 Non-covered Recipient Entity
GHASSAN HADI MD INC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753283861
Principal investigator 1 AKEBIA THERAPEUTICS INC $2,224.04 05/11/2020 Non-covered Recipient Entity
GHASSAN HADI MD INC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753283675
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,932.30 05/06/2020 Non-covered Recipient Entity
GHASSAN HADI MD INC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753283523
Principal investigator 1 AKEBIA THERAPEUTICS INC $10,634.10 05/04/2020 Non-covered Recipient Entity
GHASSAN HADI MD INC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753283289
Principal investigator 1 Allergan, Inc. $10,000.00 04/27/2020 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
Open-label Extension Study of Relamorelin for the treatment of diabetic gastroparesis (DG) No dispute reported 06/30/2026 721272943
Principal investigator 1 Allergan, Inc. $500.00 04/27/2020 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
Open-label Extension Study of Relamorelin for the treatment of diabetic gastroparesis (DG) No dispute reported 06/30/2026 721272949
Principal investigator 1 Allergan, Inc. $385.00 04/23/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 721272261
Principal investigator 1 Allergan, Inc. $1,529.50 04/23/2020 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721272591
Principal investigator 1 Allergan, Inc. $2,701.80 04/20/2020 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721271499
Principal investigator 1 Allergan, Inc. $240.00 04/09/2020 Non-covered Recipient Entity
WESTERN INSTITUTIONAL REVIEW BOARD
OPEN-LABEL ROLLOVER STUDY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) No dispute reported 06/30/2026 721269283
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,796.40 04/01/2020 Non-covered Recipient Entity
GHASSAN HADI MD INC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753282555
Principal investigator 1 Allergan, Inc. $955.00 03/31/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 721267625
Principal investigator 1 Allergan, Inc. $371.00 03/26/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
OPEN-LABEL EXTENSION STUDY OF RELAMORELIN FOR THE TREATMENT OF DIABETIC GASTROPARESIS (DG) No dispute reported 06/30/2026 721267325
Principal investigator 1 Allergan, Inc. $4,531.50 03/25/2020 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721266843
Principal investigator 1 Allergan, Inc. $1,714.75 03/25/2020 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) No dispute reported 06/30/2026 721266917
Principal investigator 1 AKEBIA THERAPEUTICS INC $3,419.10 03/16/2020 Non-covered Recipient Entity
GHASSAN HADI MD INC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753282147
Principal investigator 1 Allergan, Inc. $700.00 03/05/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
OPEN-LABEL EXTENSION STUDY OF RELAMORELIN FOR THE TREATMENT OF DIABETIC GASTROPARESIS (DG) No dispute reported 06/30/2026 721262037
Principal investigator 1 Allergan, Inc. $1,135.00 02/27/2020 Non-covered Recipient Entity
WESTERN INSTITUTIONAL REVIEW BOARD
OPEN-LABEL ROLLOVER STUDY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) No dispute reported 06/30/2026 721261071
Principal investigator 1 AKEBIA THERAPEUTICS INC $3,960.90 02/25/2020 Non-covered Recipient Entity
GHASSAN HADI MD INC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753289433
Principal investigator 1 Allergan, Inc. $700.00 02/25/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 46-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 LONGTERM STUDY WITH A 6-WEEK RANDOMIZED-WITHDRAWAL PERIOD TO EVALUATE THE SAFETY AND No dispute reported 06/30/2026 721259709
Principal investigator 1 Allergan, Inc. $86.00 02/25/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 46-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 LONGTERM STUDY WITH A 6-WEEK RANDOMIZED-WITHDRAWAL PERIOD TO EVALUATE THE SAFETY AND No dispute reported 06/30/2026 721260059
Principal investigator 1 Allergan, Inc. $2,118.50 02/25/2020 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 721260803
Principal investigator 1 AKEBIA THERAPEUTICS INC $159.00 02/24/2020 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753286487
Principal investigator 1 Allergan, Inc. $5,120.50 02/24/2020 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721259201
Principal investigator 1 Allergan, Inc. $13,110.00 02/24/2020 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721259203
Principal investigator 1 Allergan, Inc. $6,293.75 02/17/2020 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721258009
Principal investigator 1 AKEBIA THERAPEUTICS INC $3,182.40 02/13/2020 Non-covered Recipient Entity
GHASSAN HADI MD INC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753288905
Principal investigator 1 AKEBIA THERAPEUTICS INC $471.00 02/11/2020 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753286489
Principal investigator 1 AKEBIA THERAPEUTICS INC $3,985.20 02/05/2020 Non-covered Recipient Entity
GHASSAN HADI MD INC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753288503
Principal investigator 1 Allergan, Inc. $327.00 02/04/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 46-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 LONGTERM STUDY WITH A 6-WEEK RANDOMIZED-WITHDRAWAL PERIOD TO EVALUATE THE SAFETY AND No dispute reported 06/30/2026 721255693
Principal investigator 1 Allergan, Inc. $115.00 01/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 721251335
Principal investigator 1 Allergan, Inc. $2,964.00 01/23/2020 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 721250631
Principal investigator 1 Allergan, Inc. $8,041.75 01/20/2020 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721248771
Principal investigator 1 AstraZeneca Pharmaceuticals LP $720.00 01/16/2020 Non-covered Recipient Entity
Ghassan E Hadi Md
A Phase 3 Randomized Double Blind Placebo Controlled Study Evaluating the Safety and Efficacy of Roxadustat AZD9941 for the Treatment of Anemia in Chronic Kidney Disease Patients not on Dialysis No dispute reported 06/30/2026 736738425
Principal investigator 1 AKEBIA THERAPEUTICS INC $11,610.61 01/02/2020 Non-covered Recipient Entity
GHASSAN HADI MD INC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753287707